Your browser version may not work well with NCBI's Web applications. More information here...
1: Acta Dermatovenerol Alp Panonica Adriat. 2005 Sep;14(3):115-9. Links

Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.

Angelova-Fischer I, Tsankov N.

Department of Dermatology, University of Medicine, 1 S.G.Sofiiski Blvd, 1431 Sofia, Bulgaria. i.angelova_fischer@abv.bg

Leukotrienes are potent proinflammatory mediators derived from of arachidonic acid through the 5- lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a rationale for the use of pharmacological agents to antagonize their effects in the treatment of atopic dermatitis. We report 2 cases of severe atopic dermatitis successfully treated with montelukast as a single therapeutic agent in a daily dose of 10 mg for 8 weeks when corticosteroid treatment was contraindicated or failed to control the disease. Our observations suggest that montelukast may be used as an alternative steroid sparing medication for severe atopic dermatitis, especially in patients with associated asthma and rhinitis.

PMID: 16200338 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Montelukast (Singulair® )

    Montelukast is used to prevent difficulty breathing, chest tightness, wheezing and coughing caused by asthma. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise. Montelukast is also...

  • Source: AHFS Consumer Medication Information